Global Antibody Drug Conjugate Market: By Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies) - Forecast 2027
ID: MRFR/Pharma/0607-HCR | February 2021 | Region: Global | 140 pages
Market Scenario
Antibody drug conjugates comprise three parts, mainly a specific antibody for binding, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the antibody. These drug conjugates are regarded to be the new age of therapeutic agents. The combine effect of targeting specific types of cells and the killing ability of cytotoxic drugs make this drug conjugate the ideal one for treatment of various cancers. The success of this technology has become possible only with increasing technological advancements. The potential of a cytotoxic drug embedded in the antibody drug conjugate is increased by 100–1000 fold more than the potential of cytotoxic drug when it acts alone.
The key antibody-drug conjugates currently under the clinical trial is glembatumumab vedotin (CDX-011), a monoclonal antibody-drug conjugate developed by Celldex Therapeutics Inc. Other drugs under clinical trials include Polatuzumab Vedotin (RG7596) developed by Roche/Genentech, Indatuximab Ravtansine (BT-062) developed by Biotest, Anti-guanylyl Cyclase C/Anti-GCC ADC developed by Takeda: Millennium, Anti-PSMA ADC Therapeutics developed by Progenics Pharmaceuticals; Coltuximab Ravtansine (SAR3419) developed by Sanofi, Pinatuzumab Vedotin (RG7593) developed by Roche/Genentech, and Lifastuzumab Vedotin (RG7599) developed by Roche/Genentech.
The advancement in the medical technology is driving the global market for antibody drug conjugates. Moreover, the rising cases of cancer, increase in obese population, and growing ageing population are some of the key driving factors for the market. Further over, preclinical research, the increasing research activities on antibody therapies, more research on advanced drug discoveries, increasing research on oncology diseases, the growing collaboration between research institutes, and biopharmaceuticals and biotechnology companies are acting as a fuel to the market and are expected to drive the market of antibody drug conjugates within the forecast period. However, the high cost of procedures and the lack of fund could be the restraints for the growth of this market.
The global market of antibody drug conjugate is expected to grow at a CAGR of approximately 19% during the forecast period, 2017–2023.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Intended Audience
- Antibody drug conjugate manufacturing companies
- Suppliers and distributors of antibody drug conjugate
- Healthcare service providers
- Health insurance players
- Research and consulting firms
- Medical research institutes
- Venture capitalists
- Community centers
Segmentation
The global antibody drug conjugate market is segmented on the basis of type, product, technology, application, and end-user.
On the basis of type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.
On the basis of application, the global antibody drug conjugate market is segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further divided into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).
On the basis of product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.
On the basis of technology, the global antibody drug conjugate market is classified into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.
On the basis of end-user, the global antibody drug conjugate market is classified into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others.
Regional Analysis
The global antibody drug conjugate market consists of four regions, namely, America, Europe, Asia Pacific, and the Middle East and Africa.
Americas dominated the global antibody drug conjugate market owing to the technological innovation, advancement in manufacturing processes, contribution of nanotechnology for developing Antibody Drug Conjugates (ADC). There are only three antibody drug conjugates that have received approval from the U.S. Food and Drug Administration (FDA). The US is the largest market among other countries such as Mexico, Canada, and others. Though, this technology is being developed by many large pharmaceutical companies, the success rate is of developing an ADC very less and lies with very few companies.
The European antibody drug conjugate market is the second largest market followed by the Asia Pacific regions.
Asia Pacific is the emerging market in the global antibody drug conjugate market. The rising awareness among consumers along with growing government initiatives are driving the antibody drug conjugate market in this region. There are many products under the pipeline. These developments are carried out under license agreements.
Key Players
Some major players in the global antibody drug conjugate market include Seattle Genetics (US), ImmunoGen, Inc. (US), Roche Holding AG (Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US), and others.
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | Significant Value |
| CAGR | 19% |
| Base Year | 2017 |
| Forecast Period | 2027 |
| Historical Data | 2016 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors and Trends |
| Segments Covered | Type, product, technology, application, and end-user |
| Geographies Covered | North America, Europe, Asia-Pacific and Rest of the World (RoW) |
| Key Vendors | Seattle Genetics (US), ImmunoGen, Inc. (US), Roche Holding AG (Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US) |
| Key Market Opportunities | Research activities |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
The global market of antibody drug conjugate is projected to grow at a CAGR of approximately 19% during the forecast period, 2017–2023.
Advancement in medical technology.
North America holds the largest share in the global antibody drug conjugate market followed by Europe and Asia Pacific, respectively.
ImmunoGen, Inc. (US), Seattle Genetics (US), Roche Holding AG (Switzerland), Concortis Biotherapeutics (US), Genentech (US), Agensys, Inc. (US), Immunomedics (US), Antikor (UK), Pfizer Inc. (US), Millennium Pharmaceuticals (US), Celldex Therapeutics (US), AbbVie Inc. (US), Astellas Pharma/Agensys (Japan), Bayer HealthCare (Germany), Progenics Pharmaceuticals (US), Synthon (US), Oxford BioTherapeutics (US), Mersana Therapeutics (US), and Heidelberg Pharma (Germany), are some of the major players operating in the global antibody drug conjugate market.
Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global antibody drug conjugate market adopt to gain a larger competitive advantage.